<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740868</url>
  </required_header>
  <id_info>
    <org_study_id>1000048243</org_study_id>
    <nct_id>NCT02740868</nct_id>
  </id_info>
  <brief_title>Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease</brief_title>
  <official_title>Development of Hyperpolarized Xenon-129 Lung Magnetic Resonance Imaging: Comparative Pilot Study of Healthy Volunteers and Participants With Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital for Sick Children</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate image quality and reproducibility of Xenon-129 Magnetic&#xD;
      Resonance Imaging (MRI) and to evaluate changes in lung structure and function in&#xD;
      participants with cystic fibrosis (CF) and asthma compared to healthy controls using&#xD;
      Xenon-129 MRI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperpolarized noble gas magnetic resonance (MR) lung imaging is a relatively new imaging&#xD;
      method that allows depiction of both lung function and morphology. Hyperpolarized gases are a&#xD;
      new class of MR contrast agent which, when inhaled, provide high temporal and spatial&#xD;
      resolution MR images of the lung airspaces. Since no ionizing radiation is involved,&#xD;
      hyperpolarized gas MR imaging is ideal for the evaluation of lung diseases especially in&#xD;
      children. With hyperpolarized gases, the nuclear spins of the gas atoms are brought into&#xD;
      alignment outside of the MR scanner via a process called optical pumping; this yields high&#xD;
      polarizations and permits visualization of the lung airspaces with MR imaging (despite the&#xD;
      low physical density of the gas in the lung). Two non-radioactive (i.e. stable) isotopes of&#xD;
      noble gases helium-3 and xenon-129 can be hyperpolarized. Until recently, higher&#xD;
      polarizations could be achieved with helium-3 than with xenon-129, so in humans, helium-3 was&#xD;
      more commonly used for hyperpolarized gas MR imaging of the lungs. Recently, the technology&#xD;
      has been developed to provide large quantities of highly polarized xenon-129. Helium-3 gas is&#xD;
      also extremely expensive and since there are limited reserves of the gas, difficult to&#xD;
      procure for research. Unlike helium-3, since xenon-129 is naturally present in the&#xD;
      atmosphere, it is less expensive and easier to procure for imaging.&#xD;
&#xD;
      Several applications of xenon-129 MR imaging are under development, including&#xD;
      diffusion-weighted and relaxation-weighted imaging. These techniques take advantage of the&#xD;
      fact that the rate of loss of xenon-129 polarization is significantly influenced by the local&#xD;
      blood flow and concentration of molecular oxygen, as well as the restriction of xenon-129&#xD;
      diffusion by small airway space dimensions. These data can be used to create maps of the lung&#xD;
      reflecting regional ventilation/perfusion and micro-airway sizes. Other data that can be&#xD;
      obtained with xenon-129 MRI include the volumes of ventilated and unventilated lungs which&#xD;
      can subsequently be analyzed to determine the homogeneity of gas distribution within the&#xD;
      airspaces. These data can be used to study the structural and functional changes taking place&#xD;
      in the lungs associated with pulmonary diseases like CF and asthma. It might provide a&#xD;
      diagnostic tool that is able to detect pulmonary diseases more sensitively than the current&#xD;
      gold standard measurements of spirometry and plethysmography, and thus prevent irreparable&#xD;
      and irreversible damage to the lungs in the early stages of disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant differences in lung function between CF and healthy group and asthma and healthy group for ventilation defect percent (VDP) measurement</measure>
    <time_frame>1 year</time_frame>
    <description>Ventilation defect percent (VDP) will measure the unventilated lung volume normalized to the total lung volume to give a ventilation defect percent (VDP) value. VDP will range from 0-100% with 0 being healthy.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy Participants ages 8 and older. Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cystic Fibrisos</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with cystic fibrosis ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with asthma ages 8 and older.Participants with inhale hyperpolarized xenon-129 which is used as a contrast agent for lung imaging. Participants will undergo magnetic resonance imaging and lung clearance index.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xenon-129</intervention_name>
    <description>Xenon gas to be inhaled by research participants</description>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_label>Cystic Fibrisos</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <other_name>129Xe</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Lung imaging will be performed for participants using MRI for all 3 arms</description>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_label>Cystic Fibrisos</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lung Clearance Index</intervention_name>
    <description>Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms</description>
    <arm_group_label>Asthma</arm_group_label>
    <arm_group_label>Cystic Fibrisos</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
    <other_name>LCI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants male and female aged 8 years old and older.&#xD;
&#xD;
          2. Participants have no smoking history.&#xD;
&#xD;
          3. For participants with CF and asthma, a clinical diagnosis is necessary and they should&#xD;
             be at their baseline level of symptom control based on history.&#xD;
&#xD;
          4. Participants should have a FEV1%pred value greater than 40%.&#xD;
&#xD;
          5. Participant understands the study procedures and is willing to participate in the&#xD;
             study as indicated by signature on the informed consent or assent.&#xD;
&#xD;
          6. Participant must be able to perform a breath hold for 16s.&#xD;
&#xD;
          7. Participant able to perform reproducible pulmonary function tests (i.e., the 3 best&#xD;
             acceptable spirograms have FEV1 values that do not vary more than 5% of the largest&#xD;
             value or more than 100 ml, whichever is greater).&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant is, in the opinion of the investigator, mentally or legally incapacitated,&#xD;
             preventing informed consent/assent from being obtained, or cannot read or understand&#xD;
             the written material.&#xD;
&#xD;
          2. Participant has a history of cardiovascular disorders including coronary&#xD;
             insufficiency, cardiac arrhythmias, severe hypertension.&#xD;
&#xD;
          3. Participant has had a cold or respiratory infection in the last four weeks.&#xD;
&#xD;
          4. Participant requires supplemental oxygen or has a daytime room air oxygen saturation â‰¤&#xD;
             95%.&#xD;
&#xD;
          5. Participant is unable to perform spirometry or plethysmography maneuvers.&#xD;
&#xD;
          6. Participant is pregnant or lactating.&#xD;
&#xD;
          7. In the investigator's opinion, participant suffers from any physical, psychological or&#xD;
             other condition(s) that might prevent performance of the MRI, such as severe&#xD;
             claustrophobia.&#xD;
&#xD;
          8. Participant has an MRI incompatible device or any metal in their body which cannot be&#xD;
             removed, including but not limited to pacemakers, neurostimulators, biostimulators,&#xD;
             implanted insulin pumps, aneurysm clips, bio prosthetic, artificial limb, metallic&#xD;
             fragment or foreign body, shunt, surgical staples (including clips or metallic sutures&#xD;
             and/or ear implants).&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giles Santyr, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giles Santyr, PhD</last_name>
    <phone>416-813-7654</phone>
    <phone_ext>301394</phone_ext>
    <email>giles.santyr@sickkids.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Braganza, BSc</last_name>
    <phone>4167281662</phone>
    <phone_ext>307937</phone_ext>
    <email>sharon.braganza@sickkids.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giles Santyr, PhD FCCPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 19, 2015</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Hospital for Sick Children</investigator_affiliation>
    <investigator_full_name>Giles Santyr</investigator_full_name>
    <investigator_title>Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging,cystic fibrosis,asthma,healthy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xenon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

